A sophisticated gold nanoconjugate system (Au-C225-p53) containing gold nanoparticles, cetuximab, and pCMVp53 plasmid revealed promising results for targeting ovarian cancers in vitro (SKOV-3 cells) and in vivo (SKOV-3 xenograft mice) [73]. This evidence concerns the gene TP53 and ovarian cancer.